Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.
Drug Development
ABEC to expand global manufacturing network with new Wilson facility
Solstice Oncology secures $225m to drive porustobart’s development for cancer
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
Gilead launches research facility in US for new medicine development
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
LSTM opens $23m robotic AI lab for infection research
Novartis India acquires Pfizer brands for $132m
